An open-label, multicentric, phase Ib/II study to assess the safety and efficacy of AsiDNATM, a DNA repair inhibitor, administered intravenously in addition to Niraparib in patients with relapsed platinum sensitive ovarian cancer already treated with Niraparib since at least 6 months (RevoCAN)

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 09 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etidaligide (Primary) ; Niraparib
Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms REVOCAN

Most Recent Events

05 Dec 2024 Status changed from suspended to discontinued.
24 Oct 2023 Status changed from recruiting to suspended. Study was stopped after 12 pts (the company stopped the fabrication of AsiDN for new pts).
24 Oct 2023 Preliminary results presented at the 48th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight